Keytruda, known scientifically as pembrolizumab, is an immunotherapy drug developed by Merck & Co. It was first approved by the U.S. Food and Drug Administration (FDA) in 2014 for advanced melanoma and has since received approval for treating 14 different cancer types in India, including non-small cell lung cancer, triple-negative breast cancer, and renal cell carcinoma. Oncologists emphasize that Keytruda works by blocking the PD-L1 protein on cancer cells, which prevents these cells from evading the immune system. This allows the body to recognize and attack the tumors more effectively.

Unlike traditional chemotherapy, which can lead to temporary disease control, immunotherapy with Keytruda can result in sustained remission for some patients, offering the potential for long-term survival. It is particularly effective in challenging areas like the brain, where some patients have shown significant responses. However, Keytruda is not without its limitations; it can cause immune-related adverse events affecting various organs. While most side effects are manageable, some can be severe, highlighting the importance of patient education and monitoring.

The selection of appropriate candidates for Keytruda treatment relies on biomarker tests that assess factors such as PD-L1 expression and tumor mutational burden. This personalized approach aims to ensure that the right patients receive the right treatment, maximizing the benefits of this innovative therapy.